Abstract
Malaria is a vector-borne disease that is considered to be one of the most serious public health problems due to its high global mortality and morbidity rates. Although multiple strategies for controlling malaria have been used, many have had limited impact due to the appearance and rapid dissemination of mosquito resistance to insecticides, parasite resistance to multiple antimalarial drug, and the lack of sustainability. Individuals in endemic areas that have been permanently exposed to the parasite develop specific immune responses capable of diminishing parasite burden and the clinical manifestations of the disease, including blocking of parasite transmission to the mosquito vector. This is referred to as transmission blocking (TB) immunity (TBI) and is mediated by specific antibodies and other factors ingested during the blood meal that inhibit parasite development in the mosquito. These antibodies recognize proteins expressed on either gametocytes or parasite stages that develop in the mosquito midgut and are considered to be potential malaria vaccine candidates. Although these candidates, collectively called TB vaccines (TBV), would not directly stop malaria from infecting individuals, but would stop transmission from infected person to non-infected person. Here, we review the progress that has been achieved in TBI studies and the development of TBV and we highlight their potential usefulness in areas of low endemicity such as Latin America.
| Original language | English |
|---|---|
| Pages (from-to) | 202-211 |
| Number of pages | 10 |
| Journal | Memorias do Instituto Oswaldo Cruz |
| Volume | 106 |
| Issue number | SUPPL. 1 |
| DOIs | |
| State | Published - Aug 1 2011 |
Fingerprint
Keywords
- Malaria
- Plasmodium
- Transmission blocking immunity
- Transmission blocking vaccine
- Vaccines
- Vector-borne disease
ASJC Scopus subject areas
- Microbiology (medical)
Cite this
Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America. / Arévalo-Herrera, Myriam; Solarte, Yezid; Marin, Catherin; Santos, Mariana; Castellanos, Jenniffer; Beier, John C; Valencia, Sócrates Herrera.
In: Memorias do Instituto Oswaldo Cruz, Vol. 106, No. SUPPL. 1, 01.08.2011, p. 202-211.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America
AU - Arévalo-Herrera, Myriam
AU - Solarte, Yezid
AU - Marin, Catherin
AU - Santos, Mariana
AU - Castellanos, Jenniffer
AU - Beier, John C
AU - Valencia, Sócrates Herrera
PY - 2011/8/1
Y1 - 2011/8/1
N2 - Malaria is a vector-borne disease that is considered to be one of the most serious public health problems due to its high global mortality and morbidity rates. Although multiple strategies for controlling malaria have been used, many have had limited impact due to the appearance and rapid dissemination of mosquito resistance to insecticides, parasite resistance to multiple antimalarial drug, and the lack of sustainability. Individuals in endemic areas that have been permanently exposed to the parasite develop specific immune responses capable of diminishing parasite burden and the clinical manifestations of the disease, including blocking of parasite transmission to the mosquito vector. This is referred to as transmission blocking (TB) immunity (TBI) and is mediated by specific antibodies and other factors ingested during the blood meal that inhibit parasite development in the mosquito. These antibodies recognize proteins expressed on either gametocytes or parasite stages that develop in the mosquito midgut and are considered to be potential malaria vaccine candidates. Although these candidates, collectively called TB vaccines (TBV), would not directly stop malaria from infecting individuals, but would stop transmission from infected person to non-infected person. Here, we review the progress that has been achieved in TBI studies and the development of TBV and we highlight their potential usefulness in areas of low endemicity such as Latin America.
AB - Malaria is a vector-borne disease that is considered to be one of the most serious public health problems due to its high global mortality and morbidity rates. Although multiple strategies for controlling malaria have been used, many have had limited impact due to the appearance and rapid dissemination of mosquito resistance to insecticides, parasite resistance to multiple antimalarial drug, and the lack of sustainability. Individuals in endemic areas that have been permanently exposed to the parasite develop specific immune responses capable of diminishing parasite burden and the clinical manifestations of the disease, including blocking of parasite transmission to the mosquito vector. This is referred to as transmission blocking (TB) immunity (TBI) and is mediated by specific antibodies and other factors ingested during the blood meal that inhibit parasite development in the mosquito. These antibodies recognize proteins expressed on either gametocytes or parasite stages that develop in the mosquito midgut and are considered to be potential malaria vaccine candidates. Although these candidates, collectively called TB vaccines (TBV), would not directly stop malaria from infecting individuals, but would stop transmission from infected person to non-infected person. Here, we review the progress that has been achieved in TBI studies and the development of TBV and we highlight their potential usefulness in areas of low endemicity such as Latin America.
KW - Malaria
KW - Plasmodium
KW - Transmission blocking immunity
KW - Transmission blocking vaccine
KW - Vaccines
KW - Vector-borne disease
UR - http://www.scopus.com/inward/record.url?scp=80051766424&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80051766424&partnerID=8YFLogxK
U2 - 10.1590/S0074-02762011000900025
DO - 10.1590/S0074-02762011000900025
M3 - Article
C2 - 21881775
AN - SCOPUS:80051766424
VL - 106
SP - 202
EP - 211
JO - Memorias do Instituto Oswaldo Cruz
JF - Memorias do Instituto Oswaldo Cruz
SN - 0074-0276
IS - SUPPL. 1
ER -